Search results for: 'Drug Discovery and Early Development Outsourcing Market'

23 Jul 2025  |  Asia Pacific  |  Market Research

Facility Management Industry, Southeast Asia, 2025–2030

Demand for Outsourcing and Value-added Services Driving Transformational Growth Due to Evolving Customer Needs and Technology-enabled Solutions

Infographics

×

The steady growth of the Southeast Asian facility management (FM) market is primarily driven by robust growth in developing markets in the region, offset by a lower growth rate in the mature Singapore market. The growing outsourcing culture, bolstered by asset base expansion, evolving FM needs, greater acceptance of technologies, and the sustainabi...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

This study provides forecasts for the customer service (CX) outsourcing market in the Asia-Pacific for 2023 to 2028. Improving CX has been a consistent priority for organizations across the board for the last few years, with decision-makers realizing that providing a superior CX is a must for any company that wants to stay relevant. This is bringin...

Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are work...

This issue of High-Tech Materials Technology Opportunity Engine (TOE) profiles significant advancements in high-tech materials for various enhanced industrial applications. The featured innovations include Cloud-Enabled Quantum Chemistry for Scalable Simulations, Biocatalysis Approach to Convert Waste Into Sustainable Leather Alternative, Biomass F...

The Frost Radar for the outsourced digital workplace services (ODWS) industry analyzes providers offering solutions that enhance digital workplace environments through consulting, implementation, and support services. These solutions aim to improve employee engagement, productivity, and digital dexterity by integrating advanced tools and technolog...

The lighter-than-air (LTA) and heavier-than-air (HTA) high-altitude pseudo satellite (HAPS) projects have had a long period of gestation, starting in the 1970s. Technological challenges, especially solar panel efficiency and battery density, have held the market back. The recent closing of the Google Loon project has raised questions on the feasibi...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...